ReviewHematology/oncology clinics of North America2025
The Chronic Lymphocytic Leukemia Epigenome: A Powerful and Stable Framework for Understanding Biological and Clinical Heterogeneity.
Review in Hematology/oncology clinics of North America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This review explores how epigenetic information, and in particular DNA methylation-based "epitypes," enhances our understanding of chronic lymphocytic leukemia (CLL) biology and prognosis. Epitypes correlate with B-cell maturation stages and outperform traditional biomarkers like immunoglobulin heavy chain variable region mutation status in predicting outcomes. The stability and specificity of CLL epigenetic patterns offer insights into disease history, risk stratification, and treatment response, even amid evolving therapeutic landscape. Emerging epigenetic signatures, including proliferative indices, further refine patient classification and outcome prediction, underscoring the potential clinical utility of integrating epigenetic data in CLL management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.